ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.307,83
1,36%
S&P 500
5.482,87
0,09%
US Dollar vs BRL
5,5023
0,01%
Bitcoin
61.429,84
-0,29%
Brent Oil
85,705
0,34%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. TransCode Therapeutics Inc (RNAZ)

  7. TransCode Therapeutics Inc (RNAZ) Notícias

RNAZ

TransCode Therapeutics (RNAZ)

TransCode Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:RNAZ
DataHoraFonteTítuloCódigoCompanhia
18/06/202417:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAZTransCode Therapeutics Inc
14/06/202409:00Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
13/06/202418:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
10/06/202409:45Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
10/06/202408:00GlobeNewswire Inc.Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing RequirementsNASDAQ:RNAZTransCode Therapeutics Inc
29/05/202410:15GlobeNewswire Inc.TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138NASDAQ:RNAZTransCode Therapeutics Inc
20/05/202417:00Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:RNAZTransCode Therapeutics Inc
13/05/202409:30GlobeNewswire Inc.TransCode Therapeutics Open Letter to ShareholdersNASDAQ:RNAZTransCode Therapeutics Inc
10/05/202417:50Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
15/04/202410:00GlobeNewswire Inc.TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid TumorsNASDAQ:RNAZTransCode Therapeutics Inc
03/04/202410:10GlobeNewswire Inc.TransCode Therapeutics Reports 2023 Results; Provides Business UpdateNASDAQ:RNAZTransCode Therapeutics Inc
28/03/202409:30GlobeNewswire Inc.TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical OfficerNASDAQ:RNAZTransCode Therapeutics Inc
11/03/202410:00GlobeNewswire Inc.TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer TreatmentNASDAQ:RNAZTransCode Therapeutics Inc
06/03/202418:15GlobeNewswire Inc.TransCode Therapeutics To Present At 2024 RNA Leaders Europe CongressNASDAQ:RNAZTransCode Therapeutics Inc
20/02/202410:00GlobeNewswire Inc.TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist ImmunotherapeuticNASDAQ:RNAZTransCode Therapeutics Inc
15/02/202418:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
31/01/202418:05GlobeNewswire Inc.Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock MarketNASDAQ:RNAZTransCode Therapeutics Inc
29/01/202410:30GlobeNewswire Inc.TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for CancerNASDAQ:RNAZTransCode Therapeutics Inc
22/01/202418:45GlobeNewswire Inc.TransCode Therapeutics Announces Closing of $7.25 Million Public OfferingNASDAQ:RNAZTransCode Therapeutics Inc
19/01/202423:57Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:RNAZTransCode Therapeutics Inc
19/01/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RNAZTransCode Therapeutics Inc
18/01/202415:27GlobeNewswire Inc.TransCode Therapeutics Announces Pricing of $7.25 Million Public OfferingNASDAQ:RNAZTransCode Therapeutics Inc
18/01/202412:39Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
12/01/202418:05GlobeNewswire Inc.TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEONASDAQ:RNAZTransCode Therapeutics Inc
11/01/202410:22Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:RNAZTransCode Therapeutics Inc
11/01/202410:00GlobeNewswire Inc.TransCode Therapeutics Announces 1-for-40 Reverse Stock SplitNASDAQ:RNAZTransCode Therapeutics Inc
04/01/202410:05GlobeNewswire Inc.TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and ObjectivesNASDAQ:RNAZTransCode Therapeutics Inc
18/12/202318:28Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
12/12/202310:30GlobeNewswire Inc.TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138NASDAQ:RNAZTransCode Therapeutics Inc
07/12/202318:30Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:RNAZTransCode Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:RNAZ

Seu Histórico Recente

BIT
NSCIT2749785
International Bank for R...
BIT
AIW
Almawave
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados